NEOGENOMICS INC SEC Filings

BlackRock, Inc. filed an amended beneficial ownership report for NeoGenomics, Inc. common stock. BlackRock reports beneficial ownership of 20,358,331 shares, representing 15.6% of the outstanding common stock. Of these, 19,688,877 shares carry sole voting power and all 20,358,331 shares carry sole dispositive power.

The filing states that these holdings reflect securities beneficially owned, or deemed to be beneficially owned, by certain BlackRock business units, excluding other disaggregated units. It also notes that iShares Core S&P Small-Cap ETF has an interest in NeoGenomics common stock that is more than five percent of the total outstanding common stock.

NeoGenomics, Inc. is reported to have 10,113,261 shares of its common stock beneficially owned by First Trust Portfolios L.P., First Trust Advisors L.P. and The Charger Corporation, representing 7.77% of the class. First Trust Advisors L.P. and The Charger Corporation report shared voting and shared dispositive power over these shares, while First Trust Portfolios L.P. reports no voting or dispositive power.

The position is largely held through unit investment trusts sponsored by First Trust Portfolios L.P. and other investment vehicles advised by First Trust Advisors L.P. All three reporting entities jointly file under Rule 13d-1(k)(1) and expressly disclaim beneficial ownership of the reported shares.

NeoGenomics, Inc. reported net revenue of $201,656 (dollars in thousands) for the quarter ended June 30, 2026, up from $181,330 a year earlier, with gross profit increasing to $91,878. Operating expenses declined, partly due to the absence of prior-year impairment charges, and loss from operations narrowed to $9,771 (all in thousands).

After interest income and an $11,181 gain on extinguishment of debt, NeoGenomics generated quarterly net income of $2,238 versus a prior-year net loss of $45,092 (dollars in thousands); for the first six months, it recorded a net loss of $14,868 on revenue of $388,328. Cash and cash equivalents were $145,539, and total stockholders’ equity $785,732 (dollars in thousands) as of June 30, 2026.

During the quarter, the company issued $316.3 million of 0.75% Convertible Senior Notes due 2032, using proceeds to repurchase a portion of its 2028 notes for $262.9 million in cash, enter $28.7 million of equity-classified capped call transactions, and repurchase 2,383,222 shares for $25.0 million. A subsequent civil settlement with the U.S. Department of Justice requires payment of $10.0 million and reduced a previously recorded reserve by about $1.2 million, producing a benefit in general and administrative expense.

NeoGenomics, Inc. reported strong Q2 2026 growth with total revenue of $202 million, up 11% year over year. Clinical services revenue rose 14% to $187 million, supported by 26% NGS growth. Gross profit increased to $91.9 million with gross margin at 45.6% and adjusted gross margin at 48.1%. Operating expenses fell 19%, aided by the absence of prior-year impairment charges, narrowing the operating loss to $9.8 million.

GAAP net income was $2.2 million versus a $45.1 million loss a year earlier, including an $11.2 million gain on extinguishment of debt; adjusted net income reached $6.7 million and adjusted EBITDA grew 36% to $14.5 million. The company refinanced its convertible notes through a $316 million private offering of 0.75% notes due 2032, repurchased $276 million of 0.25% notes due 2028, entered capped call transactions to limit conversion dilution, and bought back $25 million of common stock, ending the quarter with $145.5 million of cash and equivalents. Updated 2026 guidance calls for revenue of $802–$806 million, net loss of $34–$42 million, and adjusted EBITDA of $56–$58 million.

NeoGenomics, Inc. filed an amendment to correct date references in a prior current report, changing erroneous “June 20, 2026” mentions in Items 7.01 and 8.01 to the correct date, July 20, 2026. The amendment restates those items but does not update any other prior disclosure.

The company had voluntarily conducted an internal investigation into the compliance of certain consulting and service agreements with federal healthcare laws and regulations and notified the Office of Inspector General of the U.S. Department of Health and Human Services in November 2021. On July 20, 2026, NeoGenomics finalized a civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving the government’s investigation concerning consulting services provided to certain health care providers. Under the settlement, NeoGenomics will pay $9,813,260. As of March 31, 2026, it had accrued a reserve of $11.2 million for potential damages and liabilities. The settlement agreement states it is neither an admission of liability by the company nor a concession by the United States that its claims are not well founded.

NeoGenomics, Inc. reported that it finalized a civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving a government investigation into consulting services provided to certain health care providers under its Laboratory Collaboration Initiative program.

The company had voluntarily conducted an internal review of compliance with federal healthcare laws and self-disclosed the matter to OIG-HHS in November 2021. Under the settlement, NeoGenomics agreed to pay $9,813,260 plus interest at 4.250% per annum from January 16, 2026. As of March 31, 2026, it had accrued a reserve of $11.2 million for potential damages and liabilities associated with this investigation. The settlement agreement states it is neither an admission of liability by NeoGenomics nor a concession by the United States regarding its claims.

NEOGENOMICS INC director Carolyn S. Starrett reported receiving new equity awards. On 2026-06-23, she was granted 14,125 Restricted Stock Units, each representing one share of common stock when vested. She was also granted stock options for 9,784 shares of common stock at an exercise price of $11.20 per share, expiring on 2036-06-01. A footnote states that once vested, the common shares underlying these awards are not subject to expiration.

NEOGENOMICS INC director Carolyn S. Starrett filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing shows no reported transactions or holdings at this time, indicating it is an initial disclosure establishing her status as a reporting person.

NeoGenomics, Inc. filed a current report announcing that its Board of Directors increased in size from nine to ten members and appointed Carolyn S. Starrett as a new director, effective immediately. She will serve until the 2027 annual meeting of stockholders and then until a successor is elected and qualified.

Starrett brings more than 25 years of experience in data, technology, and oncology, including executive roles at Flatiron Health, where she served as CEO and Board Director, and prior board service at Foundation Medicine. NeoGenomics highlights her expertise in real-world data, AI, and analytics to support its oncology diagnostics and precision medicine strategy.